European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

Blueprint Medicines Corporation BPMC announced that the European Medicines Agency (“EMA”) has validated its Type II variation marketing authorization application seeking approval for its lead ...

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ...

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ...

AYVAKYT will be available in 100 mg, 200 mg and 300 mg dose strengths, and the recommended starting dose is 300 mg once daily.

Revenues were $96.1 million in the first quarter of 2024, including $92.5 million of net product revenues from sales of AYVAKIT/AYVAKYT and $3.6 million in collaboration revenues.

The European Commission (EC) has approved Blueprint Medicines’ Ayvakyt (avapritinib) as the first treatment for indolent systemic mastocytosis (ISM). Systemic mastocytosis (SM) is a rare ...

Ayvakyt receives a positive opinion from the CHMP for the treatment of adults with advanced systemic mastocytosis The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...

The drug is marketed under the trade name Ayvakit in the United States. Ayvakyt is the first highly effective treatment option to get the EU nod for PDGFRA D842V mutant GIST, a rare form of cancer.

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle ...